Richard K Capling1, Bahar Bastani. 1. Division of Nephrology, Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis, Missouri 63110, USA.
Abstract
GOAL: Report the natural coarse of hepatorenal syndrome in 4 patients who were maintained on chronic hemodialysis. BACKGROUND: The diagnosis of hepatorenal syndrome carries a grave prognosis with a mortality rate >90% and a median survival time of <2 weeks without orthotopic liver transplantation. STUDY: We report the clinical course of 4 patients with hepatorenal syndrome who underwent long-term (greater than 3 weeks) hemodialysis in an attempt to bridge them to orthotopic liver transplantation. The etiologies of cirrhosis were: chronic hepatitis C infection (n = 2), alcoholic liver disease (n = 1), and primary sclerosing cholangitis (n = 1). RESULTS: Mean survival time on hemodialysis was 236 days (range: 31 to 460 days). All patients survived their initial hospitalization and were discharged from the hospital. However, only one patient received orthotopic liver transplantation. Mean number of hospital admissions was 11 (range: 4 to 18) while receiving hemodialysis at an average rate of 2.2 (range: 1.1 to 5) admissions/patient month. Mean number of days spent in hospital while on hemodialysis support was 85 days (range: 15 to 199 days) at an average rate of 11.2 (range: 8.3 to 15) hospital days/patient month. An average of 33% (range: 26% to 48%) of the days of the prolonged survival on hemodialysis was spent in hospital. CONCLUSION: Although our 4 patients with hepatorenal syndrome demonstrated long-term survival with hemodialysis, their prolonged survival was at the cost of a very heavy burden of morbidity and in-patient stay. The advisability of maintenance hemodialysis in patients with hepatorenal syndrome should be judged on an individual basis.
GOAL: Report the natural coarse of hepatorenal syndrome in 4 patients who were maintained on chronic hemodialysis. BACKGROUND: The diagnosis of hepatorenal syndrome carries a grave prognosis with a mortality rate >90% and a median survival time of <2 weeks without orthotopic liver transplantation. STUDY: We report the clinical course of 4 patients with hepatorenal syndrome who underwent long-term (greater than 3 weeks) hemodialysis in an attempt to bridge them to orthotopic liver transplantation. The etiologies of cirrhosis were: chronic hepatitis C infection (n = 2), alcoholic liver disease (n = 1), and primary sclerosing cholangitis (n = 1). RESULTS: Mean survival time on hemodialysis was 236 days (range: 31 to 460 days). All patients survived their initial hospitalization and were discharged from the hospital. However, only one patient received orthotopic liver transplantation. Mean number of hospital admissions was 11 (range: 4 to 18) while receiving hemodialysis at an average rate of 2.2 (range: 1.1 to 5) admissions/patient month. Mean number of days spent in hospital while on hemodialysis support was 85 days (range: 15 to 199 days) at an average rate of 11.2 (range: 8.3 to 15) hospital days/patient month. An average of 33% (range: 26% to 48%) of the days of the prolonged survival on hemodialysis was spent in hospital. CONCLUSION: Although our 4 patients with hepatorenal syndrome demonstrated long-term survival with hemodialysis, their prolonged survival was at the cost of a very heavy burden of morbidity and in-patient stay. The advisability of maintenance hemodialysis in patients with hepatorenal syndrome should be judged on an individual basis.
Authors: Andrew S Allegretti; Xavier Vela Parada; Nwamaka D Eneanya; Hannah Gilligan; Dihua Xu; Sophia Zhao; Jules L Dienstag; Raymond T Chung; Ravi I Thadhani Journal: Clin J Am Soc Nephrol Date: 2017-11-09 Impact factor: 8.237
Authors: Marco Olivera-Martinez; Marco Olivera Martinez; Harlan Sayles; Renuga Vivekanandan; Sharlene D' Souza; Marius C Florescu Journal: Dig Dis Sci Date: 2011-08-18 Impact factor: 3.199
Authors: Juan P Arab; Juan C Claro; Juan P Arancibia; Jorge Contreras; Fernando Gómez; Cristian Muñoz; Leyla Nazal; Eric Roessler; Rodrigo Wolff; Marco Arrese; Carlos Benítez Journal: World J Hepatol Date: 2016-09-08